Article Text
Abstract
Aims Acinar cell carcinomas (ACCs) are rare tumours of the exocrine pancreas accounting for about 1–2% of all pancreatic neoplasms in adults. It is therefore difficult to come across a large number of ACC cases in a single medical institution, and only a few serial studies have been published. Since ACCs present a wide variety of morphological patterns, immunohistochemical analysis is useful. In this study, the authors established a novel monoclonal antibody 2P-1-2-1 by means of a subtractive immunisation method.
Methods Immunohistochemical staining was performed using 50 primary pancreatic tumors, including 7 ACCs, 7 neuroendocrine tumours (NETs), 5 solid-pseudopapillary neoplasms (SPNs), and 31 ductal carcinomas and organs other than the pancreas.
Results Non-neoplastic acinar cells were stained diffusely, but epithelial cells of the pancreatic duct and the islets of Langerhans were not stained. In pancreatic tumours, all the seven ACCs were diffusely positive for the 2P-1-2-1 antibody. However, no positive staining was found in other pancreatic tumours including NETs, SPNs and ductal adenocarcinomas. The sensitivity and specificity of the 2P-1-2-1 antibody for ACCs were both 100%. In other organs studied, positive staining was observed only in the ectopic pancreas.
Conclusions It was shown that the 2P-1-2-1 antibody specifically stained the pancreatic acinar cells and tumours of acinar cell origin, such as ACCs. Although it remains unclear at this time to which proteins the monoclonal antibody 2P-1-2-1 is directed, it is suggested to be useful for the pathological diagnosis of ACCs and for the exclusion of other pancreatic tumours.
- Pancreas
- gastrointestinal disease
- histopathology
- monoclonal antibody
- immunopathology
- image analysis
- pancreatic cancer
- biliary
- cancer stem cells
- diagnostics
Statistics from Altmetric.com
Footnotes
Funding This work was supported by the Japan Society for the Promotion of Science (JPSP) KAKENHI (Grant-in-Aid Challenging Exploratory Research: 21659151).
Competing interests None.
Patient consent Obtained.
Ethics approval This study was approved by the ethical committee of Kurume University (09034).
Provenance and peer review Not commissioned; externally peer reviewed.